cytokines, an upregulation of adhesion molecules and MHC I and II molecules on mono/macrophages, and an expansion of inflammatory monocytes. This exaggerated inflammatory response is responsible for necrosis and organ failure and results in uncontrolled proliferation and phagocytic activity of histiocytes [2] .
Hypertriglyceridemia (fasting, greater than or equal to 265 mg/100 ml) is one of the current diagnostic criteria for HLH [2] . Several studies link hypertriglyceridemia to inhibition of lipoprotein lipase (LPL) by tumor necrosis factor-α (TNF-α), and TNF-α is a powerful autocrine and paracrine regulator of adipose tissue [3] . Indeed, many different sources of intense and prolonged T-lymphocyte/macrophage activation may be associated with dyslipidemia (particularly with hypertriglyceridemia) through inappropriate release of TNF-a, IFN-g, GM-CSF and respectively, of IL-1/IL-6, leading to adipose tissue lipolysis with increased VLDL secretion, decreased VLDL clearance, increased hepatic fatty acid synthesis, and suppression of fatty acid oxidation with HIV infection being the wellknown paradigm of this mechanism (possibly enhanced by some antiretroviral drugs).
In PubMed there are at least 70 papers in which the association leishmaniasis/(hemophagocytic or haemophagocytic) is present. Leishmania parasites have been found to be the most common protozoan trigger of acquired HLH. In a multicenter prospective study conducted to determine the frequency of HLH syndrome in children with VL, ten children out of 24 (41 %) with VL developed HLH syndrome [4] . HLH incidence in European adult population is about 1/800,000/year, with a reported prevalence of parasitic infections of 2.4 % (53 out of 2197 subjects), and of Leishmania spp. of 0.77 % (17 out of 2197) as a trigger. The clinical picture of VL with HLH initially can be indistinguishable from HLH of other etiology, potentially Dear Sir, We found very interesting the paper by Lal et al. about hypertriglyceridemia as a possible diagnostic marker of disease severity in visceral leishmaniasis (VL) [1] . However, we think that authors should also have considered the possible diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH).
HLH is a potentially fatal hyperinflammatory syndrome characterized by histiocyte proliferation and hemophagocytosis. HLH may be inherited (primary, familial) and occurs generally in infants or may be secondary to any severe infection, malignancy or rheumatologic condition and occurring in any age. HLH is diagnosed using clinical criteria developed by the HLH Study Group of the Histiocyte Society (Table 1) [2] . The mechanism behind secondary HLH is not well understood, its clinical picture may be identical to primary HLH, but there is more variability in severity and outcome. HLH is considered due to a deficiency in cytolytic activity resulting in persistent activation of lymphocytes and histiocytes. This uncontrolled immune response leads to hypersecretion of pro-inflammatory leading to misdiagnoses and inappropriate therapies [5] . However, hypergammaglobulinemia in a patient with HLH should raise suspicion for VL as potential trigger because this is a feature not commonly reported for other forms of HLH [5] .
We think that HLH should be considered in severe cases of VL especially in those cases that do not promptly respond to specific treatment, and, on the contrary, the diagnosis of VL must be considered in children with HLH if they live or have travelled in VL endemic areas. The diagnosis of HLH must be pursued using the HLH 2004 diagnostic criteria (Table 1) , while the diagnosis of VL must be pursued using appropriate and sensitive methods such as PCR testing of bone marrow specimens.
The preferred treatment for VL in the more economically developed countries is liposomal amphotericin B. Alternative medications are drugs containing pentavalent antimony, or miltefosine. The therapy of HLH includes steroids, cyclosporine A, etoposide, T-lymphocyte directed antibodies, and other biologicals; hematopoietic stem cell transplantation is the only way to cure hereditary HLH. Case reports and small series anecdotally have reported the successful use of liposomal amphotericin B or pentavalent antimony in VL complicated by HLH.
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